8-K
filed April 7, 2026, 7:59 PM ET
ticker KPRX
CIK 0001372514
other material
confidence high
sentiment positive
materiality 0.70
Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M
KIORA PHARMACEUTICALS INC
- Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.
- Sole investors: Perceptive Advisors and ADAR1 Capital Management; no placement agent engaged.
- Each unit: 1 common share (or pre-funded warrant) + 4 Tranche A-1 + 1 Tranche A-2 warrants at $2.543.
- All warrants exercisable at $1.94/share; A-1 term ≤9 months (30 days after strategic transaction), A-2 ≤4 years (30 days after Phase 3 enrollment).
- Proceeds for general corporate purposes, including R&D and business development.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KIORA PHARMACEUTICALS INC issued pre-funded Common Stock purchase warrants to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share of warrant to certain institutional investors for combined purchase price of $2.5429 per Pre-Funded Warrant, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant.
- Security
- warrant
- Shares
- pre-funded Common Stock purchase warrants to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share
- Purchaser
- certain institutional investors
- Consideration
- combined purchase price of $2.5429 per Pre-Funded Warrant, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant
Exact text from the filing
On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share, (iii) Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share (“the Tranche A-1 Warrants”), and (iv) Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share (the “Tranche A-2 Warrants”). The combined p
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KIORA PHARMACEUTICALS INC issued Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share of warrant to certain institutional investors for included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou.
- Security
- warrant
- Shares
- Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share
- Purchaser
- certain institutional investors
- Consideration
- included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou
Exact text from the filing
A-2 Warrants”). The combined purchase price for each Private Placement Share, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5430 and the combined purchase price for each Pre-Funded Warrant, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5429, which price
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KIORA PHARMACEUTICALS INC issued 438,471 shares of Common Stock of common stock to certain institutional investors for combined purchase price of $2.5430 per Private Placement Share, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant.
- Security
- common stock
- Shares
- 438,471 shares of Common Stock
- Purchaser
- certain institutional investors
- Consideration
- combined purchase price of $2.5430 per Private Placement Share, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant
Exact text from the filing
On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share, (iii) Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share (“the Tranche A-1 Warrants”), and (iv) Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share (the “Tranche A-2 Warrants”). The combined p
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KIORA PHARMACEUTICALS INC issued Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share of warrant to certain institutional investors for included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou.
- Security
- warrant
- Shares
- Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share
- Purchaser
- certain institutional investors
- Consideration
- included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou
Exact text from the filing
A-2 Warrants”). The combined purchase price for each Private Placement Share, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5430 and the combined purchase price for each Pre-Funded Warrant, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5429, which price
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at expected aggregate gross proceeds at closing of approximately $5.0 million and potential future warr (effective 2026-04-03).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- expected aggregate gross proceeds at closing of approximately $5.0 million and potential future warr
- Effective
- 2026-04-03
Exact text from the filing
On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”),
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.